Moat.
Speed.
Allocation.
The platform moat that survives 2028 is being chosen this year.
This briefing tells you which platform moats survive 2028 in biotech and research as AI rewrites build economics. Read it before your R&D allocation locks for the decade.
The 10-page briefing. Worth 20 minutes.
One email. One PDF. Worth twenty minutes of your week.
We send it once. Work emails only.
Monday 9:15, R&D tech review. Validation cycle time on the last eCTD release flat against last quarter. Bioinformatics agent adoption at sixty-four percent. Your Head of Bioinformatics opens with the dashboard. Your phone buzzes. Two senior regulatory architects had recruiter calls from Recursion last week. Your CEO forwarded a partnership pitch from Insilico Medicine on your second indication. Your CFO sent the Shopify R&D-percentage line with one note: "What's our equivalent for digital R&D?"
You are not running one digital R&D function. You are running two, and only one is on your scorecard. One funds what you already validate and ship. The other funds what has to exist by 2028: the encoded programme-execution intelligence in three senior heads, the structured retrievable graph of fifteen years of regulatory submissions, the validation pathway for AI-augmented work your CSV team has not built yet.
The discovery moat that matters in 2028 is not above the model layer. It is in the encoded judgment underneath it.
This is the question your CEO is already asking. The briefing below is what you want in your hand before the next R&D tech review.
Build Velocity. Product Defensibility. R&D Capital Allocation.
Three questions every specialty biotech CTO is tracking. The second is the crux. The other two are how you earn the right to answer it.
Is our digital R&D speed shipping validated work, or notebooks that fail audit?
Foundation-model assist on eCTD and bioinformatics is at sixty percent adoption. Validation cycle time flat. The auditor finds traceability gaps the new pipeline never produced. Pfizer, Novartis, AstraZeneca spent seven years on data-strategy foundations that let agents ship inside GxP.
What does our firm encode that an AI-native discovery startup cannot copy?
Recursion has phenomic data Insilico does not. Insilico has generative chemistry Iktos does not. None of them have your firm's twenty years of programme-execution intelligence. It sits in three senior heads. Two of them had recruiter calls last month.
Is our digital R&D budget one instrument or two?
Plateau capital runs the existing platform at lower unit cost. Compounding capital builds the encoded-judgment moat that has to exist by 2028. On one hurdle rate the first wins every quarter. On one scorecard the second does not exist.
What you get when you download
An 11-page report for CTOs, CPOs, and Heads of Digital R&D at mid-market European specialty biotechs, CDMOs, and diagnostics firms. Designed to be read in one sitting before your next R&D tech review.
Your industry, your digital R&D function, and why they are one problem
What is happening to mid-market specialty biotech: AI-native discovery firms absorbing the moat your firm built over decades, EU HTA expansion, EU AI Act high-risk scope on clinical decision support. What is happening inside your digital R&D function: foundation-model adoption up, validation cycle time flat, the AI-strategy ownership list your seat is not on.
Four moves across build engine, platform and data, product thesis, and R&D bench
Lead the IT-Quality-Assurance working group on validation strategy for AI-augmented work. Build the encoded-judgment moat through senior-judgment encoding, programme-data restructuring, and sponsor data-rights renegotiation. Own the encoded moat, partner selectively. Rebuild the junior pathway around senior and agent pairing.
Five questions for your next R&D tech review
Is your digital R&D budget one instrument or two? Name the AI-native discovery firm in your indication. How many months to reconstruct IND reasoning if your senior architect leaves for Recursion tomorrow? Where did the freed hours from agent adoption go? Is your Q1 boundary agreement with the CEO and CSO written?
Calibrated for each seat at the table.